1,4-diisobutoxy-but-2-yne

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,4-diisobutoxy-but-2-yne
• 英文别名: Butin-(2)-diol-(1.4)-diisobutylaether；1,4-Diisobutoxy-but-2-in；1,4-Bis(2-methylpropoxy)but-2-yne
• 化学式: C₁₂H₂₂O₂
• 分子量: 198.305
• InChiKey: ONYCQYYBINTFTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  acetylene-bis-magnesium bromide 、 alkaline earth salt of/the/ methylsulfuric acid 生成 1,4-diisobutoxy-but-2-yne
  参考文献：
  名称：

  Gauthier,D., Annales de Chimie (Cachan, France), 1909, vol. <8> 16, p. 332

  摘要：

  DOI：

文献信息

• Benzimidazole derivatives
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10017499B2

  公开（公告）日：2018-07-10

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐、酯或原药： 它们能抑制含 RNA 的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物可干扰丙型肝炎病毒的生命周期，也可用作抗病毒药物。本发明进一步涉及包含上述化合物的药物组合物，用于给丙型肝炎病毒感染者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者感染 HCV 的方法。
• LINKED DIBENZIMIDAZOLE DERIVATIVES
  申请人：Or Yat Sun

  公开号：US20100221214A1

  公开（公告）日：2010-09-02

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：Qiu Yao-Ling

  公开号：US20100233122A1

  公开（公告）日：2010-09-16

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• HEPATITIS C VIRUS INHIBITORS
  申请人：Or Yat Sun

  公开号：US20100260715A1

  公开（公告）日：2010-10-14

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US20140341851A1
  申请人：——

  公开号：US20140341851A1

  公开（公告）日：2014-11-20